Maria Giulia Zampino, MD
Education and PHD/Masters/Courses
1986 Degree of Medicine, State University of Naples, Italy. Experimental thesis on “T-Cell Lymphomas” (110/110
cum laude).
1989 Specialization in Medical Oncology, State University of Naples, Italy. Experimental thesis on “TNF-alpha and
cancer”, (70/70 cum laude).
Titles
Society Affiliations:
• Since 1988 AIOM (Associazione Italiana di Oncologia Medica)
• Since 1991 member ESMO (European Society of Medical Oncology)
• Since 1993 member ASCO (American Society of Clinical Oncology)
• Since 2003 member of the Editorial Board of the international network: START in Oncology (State-of a TheARt instrument on cancer Treatment)
Clinical Activities carried out at IEO
Since 1996 in IEO and since 2001, as Deputy Director, she has coordinated the clinical activity of Medical Care
Unit/Day Hospital Center and currently of the Unit of Gastrointestinal Oncology and Neuroendocrine Tumors. She
has the responsability to manage patients with digestive tumors with specific focus towards systemic treatment of
colorectal, small bowel and anus cancers as well as combined approaches for treatment of locally advanced or
metastatic disease.
She coordinates as medical oncologist the Taskforce/GI Multidisciplinary Board of the lower gastro-intestinal tract.
Unill 2012 she was active member of IEO Commitee on “Clinical risk management and patient safety”
Research Activities carried out at IEO
Principal Investigator of some clinical trials Phase Ib/II/III/IV on digestive tumors with specific interest about
colorectal, small intestine and anus cancers and about innovative models of integrated terapeutic strategies, as
chemo-radiotherapy and locoregional treatment for liver metastases.
Her clinical research is focused also to the evaluation of clinical and biological factors useful as predictive of
clinical response to conventional therapies and/or as prognostic markers, within the digestive cancers topics.
Passed Clinical and Research Activities
1990-1996: Milan National Cancer Institute/CRO of Basilicata first as fellow and then as associated researcher at the
Division of Medical Oncology of the National Cancer Institute of Milan. Clinical and scientific interest was mainly
oriented to the treatment of breast cancer and melanoma.
Publications
Factors predicting worse prognosis in patients affected by pT3 N0 colon cancer: long-term results of a monocentric
series of 137 radically resected patients in a 5-year period. Biffi R, Botteri E, Bertani E, Zampino MG, et al. Int J
Colorectal Dis. 2012
Combined Therapies for the Treatment of Technically Unresectable Liver Malignancies: Bland Embolization and
Radiofrequency Thermal Ablation within the Same Session. Bonomo G, Della Vigna P, Monfardini L, Orgera G,
Chiappa A, Bianchi PP, Zampino MG, Orsi F. Cardiovasc Intervent Radiol. 2012
Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment
in non metastatic anal squamous cell carcinoma. Zampino MG, Magni E, Leonardi MC, Santoro L, Petazzi E, Fodor C,
Petralia G, Trovato C, Nole' F, Orecchia R. BMC Cancer. 2011
K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Zampino MG, Magni E,
Sonzogni A, Renne G. Cancer Chemother Pharmacol. 2009
Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases.
Chiappa A, Bertani E, Makuuchi M, Zbar AP, Contino G, Viale G, Pruneri G, Bellomi M, Della Vigna P, Zampino MG,
et al. Hepatogastroenterology, 2009
Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Bozzetti F; SCRINIO Working
Group (for IEO: Zampino MG, Biffi R). Support Care Cancer. 2009
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. Lorizzo K, Fazio N, Radice D, Boselli S, Ariu
L, Zampino MG, et al. Cancer Chemother Pharmacol. 2009
Cholangiocarcinoma. Mosconi S, Beretta GD, Labianca R, Zampino MG, et al. Crit Rev Oncol Hematol. 2009
Rectal cancer. Zampino MG, Labianca R, Beretta GD, et al. Crit Rev Oncol Hematol. 2009
Capecitabine Initially Concomitant to Radiotherapy Then Perioperatively Administered in Locally Advanced Rectal
Cancer. Zampino MG, Magni E, Leonardi MC, et al. Int J Radiat Oncol Biol Phys. 2009
Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients
who need cancer therapy: a randomized trial. Biffi R, Orsi F, Pozzi S, Pace U, Bonomo G, Monfardini L, Della Vigna
P, Rotmensz N, Radice D, Zampino MG,et al. Ann Oncol. May; 2009
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced
colorectal cancer treated with gefitinib? M.G.Zampino, E.Magni, L.Santoro, et al. Cancer Chemo and Pharmacol. 2008
Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.Puppa G,
Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, Zampino MG, Franceschetti I, Capelli P, Chilosi M,
Menestrina F, Viale G, Pelosi G. Br J Cancer. 2007
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified
FOLFOX6 as first-line treatment for metastatic colorectal cancer. Zampino MG, Magni E, Massacesi C et al, Cancer.
2007
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic
Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial. C. Louvet, R. Labianca, P. Hammel, G. Lledo,
M.G. Zampino, et al. Journal of Clinical Oncology. 2005
Congresses
2013 Zampino MG: Report on “Colorectal cancer: biomolecular tests in clinical practice”, Bergamo
2010 Zampino MG et al: Circulating Tumor Cells in locally advanced rectal cancer patients undergoing neoadjuvant
treatment. In ESMO Annual Meeting/Colorectal Poster Session Discussion, Milano
2007 Zampino MG et al:. Epidermal growth factor receptor serum level may predict response in patients with
advanced colorectal cancer treated with gefitinib. In: ASCO Annual Meeting, Poster session Discussion, Chicago
(USA)
2004 Zampino MG, Lorizzo K, Massacesi C. et al, Gefitinib combined with simplified FOLFOX-6 as first-line
treatment in epidermal growth factor receptor-positive advanced colorectal cancer. In: ESMO Meeting, Poster
Session Discussion, Vienna